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2SUMMARY
Sptrx-1 is the first member of the thioredoxin family of proteins with a tissue-
specific expression pattern, found exclusively in the tail of elongating spermatids and
spermatozoa. We describe here further biochemical characterization of human Sptrx-1
protein structure and enzymatic activity. In gel filtration chromatography human Sptrx-1
eluates as a 400 kDa protein consistent with either an oligomeric form, not maintained by
intermolecular disulfide bonding, and/or a highly asymmetrical structure. Analysis of
circular dichroism spectra of fragments 1-360 and 361-469 and comparison to spectra of
full length Sptrx-1 supports a two domain organization with a largely unstructured N-
terminal domain and a folded Trx-like C-terminal domain. Functionally, Sptrx-1 behaves
as an oxidant in vitro when using selenite, but not oxidized glutathione, as electron
acceptor. This oxidizing enzymatic activity suggests that Sptrx-1 might govern the
stabilization (by disulfide cross-linking) of the different structures in the developing tail
of spermatids and spermatozoa.
3INTRODUCTION
In sexually reproducing species the fusion of the gametes is a prerequisite for the
generation of the offspring whose genetic makeup is different from both parents. This
mode of reproduction via fertilization emerged during evolution and has been
maintained in most metazoans including mammals. [1]. In higher vertebrates the
complexity of the fertilization process is increased by the advent of internal fertilization
and by the functional adaptations of the oocyte vestments. To circumvent associated
difficulties, the spermatozoon has acquired a highly specialized morphology consisting
of cytoskeletal components, which appear to have no structural counterparts in somatic
cells [2]. The most evident among these cytoskeletal structures are the perinuclear theca
(PT) of the sperm head and the outer dense fibers (ODF) and fibrous sheath (FS) of the
sperm tail [3]. The mammalian ODF and FS are composed of numerous polypeptides of
which only a few have been cloned and characterized to date (reviewed in [4]). ODF and
FS are believed to regulate the beat of the sperm flagella by adding stiffness, elastic recoil
and protection against shearing forces generated during sperm transit through
epididymis [5]. However, there is increasing evidence for a more active role of ODF and
FS in sperm function than merely structural, also supported by the fact that among their
constituent proteins there are a few displaying either enzymatic or regulatory functions.
Thioredoxins are a class of multifunctional protein disulfide reductants that
participate in different cellular processes by the reversible oxidation of cysteine residues
in their conserved active site Cys-Gly-Pro-Cys. Thioredoxins have both intracellular and
extracellular roles such as electron donor for ribonucleotide reductase, regulator of cell
growth and apoptosis, embryonic implantation, modulator of the DNA binding activity
of transcription factors, co-cytokine and as protective mechanism against oxidative stress
(reviewed in [6,7]). In the human genome, three ubiquitous forms of thioredoxins have
4been identified so far: Trx-1, a cytosolic enzyme that can translocate into the nucleus
upon certain stimuli [7]; Trx-2, a mitochondrial enzyme [8] and Txl-1/Trp32, a protein
with no function described so far [9,10]. In addition, we have recently identified two
novel members of the thioredoxin family, named Sptrx-1 and Sptrx-2, whose expression
is restricted to the haploid phase of spermatogenesis [11,12]. Sptrx-1 transiently
associates to the longitudinal columns of the FS during sperm tail assembly but does not
remain as a permanent component of the FS in the mature sperm [4]. In turn, Sptrx-2 is a
structural component of the mature FS (R. Oko and A. Miranda-Vizuete, unpublished
results). Sptrx-1 and Sptrx-2 represent the first two members of the family with tissue-
specific distribution and interestingly, both located in close association to the sperm
fibrous sheath. We present here evidence that Sptrx-1 is organized into two independent
structural domains: a 38.7 kDa unstructured polypeptide (residues 1-357) and a 12.7 kDa
Trx-like domain (residues 358-469). Characterization of Sptrx-1 in vitro suggests that the
protein behaves as a non-covalent oligomer in solution and that this organization might
modulate its redox properties. The implications of an oxidizing character of Sptrx-1 are
discussed in the light of its unique expression pattern during sperm tail formation.
5MATERIALS AND METHODS
Expression and purification of human Sptrx-1. The ORF encoding human Sptrx-1
was cloned into the BamHI-EcoRI sites of the pGEX-4T-1 expression vector and
transformed in E. coli BL21(DE3). The induction of the fusion protein was performed as
previously described [11]. Briefly, overexpressing cells were disrupted by 10 min
sonication and the supernatant was cleared by centrifugation at 15,000 x g for 30 min and
loaded onto a glutathione sepharose 4B column (Amersham Pharmacia Biotech). Binding
to the matrix was allowed to occur during 2 h at room temperature. Thrombin (5U per
mg fusion protein) was used to remove GST by incubation overnight at 4°C. The
resulting protein preparation was then subjected to ion exchange chromatography using
a HiTrap Q column (Amersham Pharmacia Biotech) and human Sptrx-1 was eluted using
a gradient of NaCl. Protein concentration was determined from the absorbance at 280 nm
using a theoretical molar extinction coefficient of 7690 M-1 cm-1, calculated using the
Protean Program included in the DNASTAR Software Package (DNASTAR Inc.).
Gel filtration chromatography. Gel filtration experiments were carried out on a
Superdex 200 HR10/30 column (Amersham Pharmacia Biotech). The column was pre-
equilibrated with 100 mM Tris-HCl pH 8.0, 100 mM NaCl. Human Sptrx-1 was applied
to the column in a volume of 5 ml at a final concentration of 2 mg/ml and the flow rate
was 5 ml/cm2/h.
MALDI-TOF mass spectrometry analysis. The spectra were acquired in the linear
mode using a Reflex III mass spectrometer from Bruker Daltonik GmbH (Germany). Data
processing and evaluation was carried out with the XMASS software (Bruker). On the
target plate, a microcrystalline layer was prepared with a saturated solution of sinapinic
6acid (Sigma) in ethanol. The samples were mixed with an equal volume of a saturated
solution of sinapinic acid in 33% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid,
and 0.5 ml of this mixture was crystallized on the microcrystalline sinapinic acid layer
[13]. Calibration of the spectra was carried out with the high mass protein standard from
Aglient Technologies that contained bovine serum albumin (66,430.2 Da), equine cardiac
myoglobin (16,951.5 Da), and equine cardiac cytochrome c (12,359.2 Da).
Human Sptrx-1 crystallization. Crystallization conditions were screened with the
sitting drop vapor diffusion method. Promising conditions were further optimized to
obtain crystals suitable for X-ray analysis. The crystallization droplet was prepared by
mixing equal volumes of protein solution (protein concentration 30 mg/ml in 10 mM
Tris-HCl pH 7.4) and reservoir solution (25% polyethylene glycol 5000 monomethyl ether
in 0.1M tris buffer pH 8.0 with the addition of 0.3M sodium acetate). The droplet was
equilibrated against 0.5 ml reservoir solution at 293 K. X-ray diffraction data were
collected at 100 K with Cu-Ka radiation using a MAR research image plate. 20 % glycerol
was added to the reservoir solution as a cryo-protectant. The data were processed with
the HKL package [14]
Circular dichroism spectroscopy. Circular dichroism spectroscopy was performed
using an Aviv 202DS spectropolarimeter (Lakewood, NJ). Spectra were obtained using
protein solutions in 100 mM potassium phosphate buffer pH 7.0 containing 10 mM NaCl
and 1 mM EDTA at protein concentrations ranging from 0.5 to 0.9 mg/ml at 25 °C in 0.01
cm cuvettes. Spectra were recorded for 8 seconds per nm between 260 and 184 nm.
Protein concentrations were determined by quantitative amino acid analysis [15].
Contributions from cuvette and solvent were removed by subtracting an identically
7recorded spectrum of buffer without protein. No signal processing (e.g. smoothing) was
used.
Enzymatic activity assays. Disulfide bond formation was measured in a reduced
model peptide, NRCSQGSCWN, (Genemed Synthesis) which was acetylated and
amidated at the N- and C- terminus, respectively by the manufacturer essentially as
described [16,17]. The peptide concentration was calculated using the molar extinction
coefficient at 280 nm of 5690 (M -1 cm-1). The oxidation reaction was performed in 100 m l of
buffer consisting of 100 mM Tris-HCl pH 7.4, 200 mM KCl, 1 mM EDTA and either 1 m M
selenite (Na2SeO3) or 2 mM GSH and 0.5 mM GSSG which corresponds to a redox
potential of –202 mV at pH 7.4. PDI or Sptrx-1 was added at a final concentration of 1-2
µM. The reaction was initiated by adding 20 m M of the reduced peptide and quenched
after different time points by addition of HCl to a final concentration of 0.2 M. No
attempt was made to control the oxygen concentration in the samples. After quenching,
the samples were immediately analysed on reverse phase HPLC (Pharmacia SMART
System) on a C18 column (2.1 mm x 10 cm) using a linear gradient of 5-25% acetonitrile,
0.1% trifluoroacetic acid in 25 min at a flow rate of 100 m l/min. Elution of the peptide
was determined by absorbance at 215 nm. The degree of peptide oxidation was
calculated from the relative peak area of the oxidized peptide and total peak area.
Control experiments were performed using fully oxidized and reduced peptide.
8RESULTS
Oligomeric structure of human Sptrx-1. In addition to the two cysteine residues in
the active site of the thioredoxin domain, human Sptrx-1 has four additional cysteine
residues located in the C-terminal thioredoxin domain [11]. Interestingly, when
determining the thioredoxin activity of recombinant Sptrx-1 we observed that prior
reduction of the protein by DTT diminished its activity, in contrast to what happens to
Trx-1. Previously, we showed that Sptrx-1 migrated anomalously (~180 kDa) on non-
denaturing PAGE thus suggesting a possible oligomeric form [11]. In an attempt to
further define the oligomeric state of Sptrx-1 in vitro, we first performed gel filtration
chromatography. As shown in Figure 1, recombinant human Sptrx-1 eluted at a position
consistent with that of a 440 kDa globular protein. With a monomeric molecular mass of
53 kDa, this result indicates that native Sptrx-1 is either oligomeric or is highly
asymmetrical. We used MALDI-TOF mass spectrometry to elucidate whether potential
Sptrx-1 oligomers are maintained by intermolecular disulfide bonds. Sptrx-1 behaves as a
single peak of 51,512 Da (Fig. 2) demonstrating that intermolecular disulfide bonding is
not responsible for the anomalous behaviour of the native protein. The average value of
the mass of Sptrx-1 determined from ten independent spectra was 51,485 Da + 0.2%,
which was significantly lower than the reported theoretical mass of human Sptrx-1
monomer (53,274 Da) [11] and indicated a difference in the primary structure. To see
whether partial N-terminal digestion could account for this difference, we performed N-
terminal sequencing of the protein, which was in agreement with that reported
previously (data not shown). The clone overexpressing human recombinant Sptrx-1 used
in these experiments was sequenced and found to lack one of the repetitive motifs in the
N-terminal domain of the protein. The expected size of this shorter variant is 51,582 Da,
which is in good agreement with the MALDI-TOF results. We have recently reported the
9mouse Sptrx-1 gene and protein [18] and found that it also lacks one of the repetitive
motifs compared to the orthologous human sequence. Interestingly, we have identified
the two human variants among several patients diagnosed of sperm tail defects and
normal controls (unpublished results).
Crystallization and preliminary X-ray analysis of human Sptrx-1 protein. To gain
more insight into Sptrx-1 three-dimensional structure we attempted the crystallization of
the full-length protein. Needle-like crystals, with a maximum dimension of about 0.4
mm, were obtained after nearly one year (Figure 3A). The crystals diffracted beyond 3.0
Å resolution and autoindexing of the diffraction data [19] suggested that the crystals
belong to space group C2, which was further confirmed by inspecting the systematic
extinctions and the Laue symmetry of the diffraction pattern (Figure 3B). A preliminary
data set was collected to 2.9 Å resolution. A total of 4105 observations were merged to
give 1823 unique reflections with a merging R factor ( S (I-<I>)/S (I)) of 0.135. The data set
is 83% complete to 2.9 Å resolution with 52% in the last shell of 3.0–2.9 Å. The cell
parameters are a=45.4, b=55.2, c=42.1, a =g =90º and b =93.7º.
With the knowledge of unit cell and the molecular weight of the protein molecule,
the crystal volume per unit of protein molecular weight (Vm), can be calculated. For
protein crystals, this value ranges from 1.6 to 3.5 Å
3
/Da, with the most commonly
observed values of Vm around 2.1 Å
3
/Da [20]. Assuming one monomer of Sptrx-1 with a
molecular weight of 51.5 kDa per unit cell, an unlikely Vm value of 0.49 Å
3
/Da is
obtained, which suggests the existence of a much smaller protein molecule in the unit
cell. Protein sequence analysis using protein from dissolved crystals verified that a
specific cleavage between residues 359 and 360 had occurred during the crystallization.
The molecular weight of the remaining residues 360-463 is 12 kDa, a value typical for
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thioredoxins, that would lead to a more realistic Vm value of 2.2 Å
3
/Da. This result
indicates that Sptrx-1 underwent cleavage during crystallization, with apparent
degradation of the N-terminal domain. Thus, crystals consisted of the remaining C-
terminal thioredoxin domain.
Sptrx-1 structural characterization using circular dichroism. Circular dichroism
spectra of the intact human Sptrx-1 (Fig. 4) are consistent with the full-length protein (1-
469) containing a majority of disordered structure as evidenced by the intense minimum
near 200 nm. To ascertain whether the polypeptide responsible for this disorder is
confined to a continuous segment of the protein, we recorded spectra of the purified N-
and C-terminal domains separately. The CD spectra of the N-terminal domain (1-357)
contained an intense negative band between 195 and 200 nm consistent with a significant
content of disordered structure. In contrast, the spectra of the C-terminal domain (358-
469) resembled that recorded of native human Trx-1. When the CD spectra of the two
domains are combined and compared to that of full-length Sptrx-1 (Fig. 4), the close
coincidence of the two spectra is strong evidence that the two domains do not influence
each others structure significantly, supporting the picture of a largely disordered N-
terminal domain and a folded C-terminal Trx-like domain.
Redox activity of human Sptrx-1 protein. We have previously reported a weak
reducing activity of human recombinant Sptrx-1 using both DTT or NADPH and
thioredoxin reductase as electron donors [11]. We sought to determine whether human
Sptrx-1 might in fact be capable of catalysing disulfide bond formation, in vitro. For this
purpose, a model peptide whose oxidized and reduced forms can be separated by HPLC
after reaction with Sptrx-1 or PDI was used. For a functional assay, an electron acceptor
is also needed. Oxidized glutathione (GSSG) is a common oxidant of protein thiols.
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However, in the presence of a glutathione redox buffer with a redox potential
corresponding to -202 mV, no activity could be detected by Sptrx-1 (Figure 5a). In the
presence of selenite (which is known to oxidize the active site of Trx-1 in a non-
stoichiometric and oxygen dependent manner [21]) Sptrx-1 oxidized the peptide at a
similar initial rate compared to PDI but with a lower final yield (Figure 5b). Similar
results were obtained using fluorometric and colorimetric assays with GSSG and selenite
(data not shown).
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DISCUSSION
The transformation of spermatids to spermatozoa (spermiogenesis) involves a
complex sequence of events by which a conventional cell is converted into a highly
organized motile structure. During spermiogenesis the spermatid undergoes striking and
unique morphological and biochemical changes that include nuclear condensation,
acrosome formation and sperm tail organization [22]. A common link for most of these
processes to occur is a progressive increase in disulfide bonding, which starts at the
spermatid stage and continues through epididymal transit [23-26]. However, despite the
prominent role of disulfide bonding in spermiogenesis, the molecular mechanisms that
regulate this process are still poorly understood, mostly due to the lack of in vitro models
of spermiogenesis.
Thioredoxins are a class of proteins typically considered as key players in redox
regulated cellular mechanisms [7]. Sptrx-1 is the first member of this family with a tissue-
specific distribution, located in the sperm tail [11]. A developmental expression analysis
through the spermatogenic cycle in rodents has shown that Sptrx-1 transiently associates
to the longitudinal columns of the sperm FS during its elongation and assembly but does
not remain as a structural component of the FS in the mature sperm [4]. When analysing
Sptrx-1 thioredoxin activity in the presence of NADPH and thioredoxin reductase we
found that preincubation of the protein with DTT (to fully reduce the protein) resulted in
a decrease of the activity compared to that of oxidized Sptrx-1, in contrast to what occurs
to Trx-1 used as control [11]. This data suggested an important role of the cysteine
residues for the maintenance of Sptrx-1 in an active conformation. We decided to further
characterize Sptrx-1 in vitro by gel filtration chromatography which indicated a very
anomalous behaviour comparable to a 400 kDa globular protein. Considering 51.6 kDa as
the size of the Sptrx-1 monomer and assuming ideal globular behaviour, the results of
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the gel filtration experiment are consistent with that of an octamer. However, MALDI-
TOF analysis of Sptrx-1 showed that the solution conformation in vitro is not maintained
by intermolecular disulfide bonding. The fact that the enzymatic activity of Sptrx-1 is
affected by reduction of the protein suggests that intramolecular disulfide bonding may
be important.
Despite extensive efforts to crystallize the native Sptrx-1 protein, the crystals
contained only the C-terminal thioredoxin domain suggesting that the N-terminal
domain is prone to spontaneous degradation. Indeed, during the Sptrx-1 purification
process, we could detect some degradation of this domain resulting in a “laddering”
pattern of bands, most probably suggesting that the spontaneous degradation occurs at
specific residues within the N-terminal domain. This spontaneous degradation might be
facilitated by the disordered structure of the N-terminal domain as shown by CD
spectroscopy.
FS is a spermatozoa cytoskeletal structure, with no counterpart in somatic cells,
characterized by its elastic rigidity to provide support to the sperm tail during its beating
[27]. This function is dependent on the tight association of the proteins that integrate the
FS, achieved through extensive disulfide bonding and resulting on its high insolubility.
As we have demonstrated, Sptrx-1 is able to function as a reductant as well as an oxidant
in vitro. Together with its spatial and temporal expression in the tail of elongating
spermatids simultaneous to the assembly of the FS, our data suggests that Sptrx-1 could
indeed participate in the regulation of this process by favouring the formation of
disulfide bonds during sperm tail morphogenesis. In addition, its dual
reducing/oxidizing activity might be required to rectify non-correct disulfide pairing
and generate the suitable ones between the different sperm FS constituents, similarly to
what occurs to the disulfide bond reshuffling activity of PDI [28]. The relatively mild
reducing and oxidizing activities of recombinant Sptrx-1 should be viewed in a wider
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perspective. First, the oxidizing activity found in vitro with the model peptide as a
substrate could be limited by the reoxidation of Sptrx-1. In the case of PDI and the
protein DsbA, this has been shown to be the rate-limiting step in similar experiments
[16,29]. Second, it is plausible that additional factors are required in the assay, most
probably testis-specific, or post-translational modifications might be necessary to achieve
a fully active protein. Third, higher activity could be obtained upon interaction with
substrates. In this context, the N-terminal domain, which is unstructured in solution,
could acquire a more structured conformation after binding to an interacting protein.
As noted previously, the morphogenesis and assembly of FS (as well as other
components of sperm tail) require stabilization by disulfide bonding between its different
constituent proteins. Therefore, failure of proper functioning of Sptrx-1 could lead to
spermatozoa tail defects, thus justifying further work on Sptrx-1 as a potential target for
male factor infertility studies.
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FIGURE LEGENDS
Figure 1. Gel filtration chromatography of human Sptrx-1. Elution profile of
human Sptrx-1 applied to a Superdex 200 columnn in a volume of 5 ml, at a final
concentration of 2 mg/ml and a flow rate of 5 ml/cm2/h. Inset shows the calibration of
the column using high and low molecular weight markers and a SDS-PAGE analysis of
an aliquote of Sptrx-1 preparation applied to the column.
Figure 2. MALDI-TOF analysis of human Sptrx-1. The spectrum shows the single,
double and triple charged ions of Sptrx-1 at m/z 51512, 25790 and 17201, respectively.
The mass determination of Sptrx-1 was carried out using the single charged ion of the
protein.
Figure 3. Crystallographic analysis of the thioredoxin domain of human Sptrx-1.
A) Monoclinic crystal of the C-terminal thioredoxin domain of Sptrx-1. The maximal
dimension of the crystal is about 0.4 mm. B) A pseudo-precession photograph (0kl layer)
showing the Laue symmetry 2/m. Systematic extinctions of k = 2n + 1 can be clearly
observed. The diffraction data were evaluated in space group P1. The outer edge of the
photograph corresponds to 4.0 Å resolution. The figure was produced with the program
PATTERN [30].
Figure 4. Circular dichroism spectra of Sptrx-1. Plot of decadic molar (mean
residue) CD, D e , as a function of wavelength for native Sptrx-1 (1-463), open circles; N-
terminal domain (1-360), filled circles; C-terminal domain (361-463), open diamonds;
combined N- and C-terminal spectra, open triangles; and human Trx-1, filled diamonds.
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Spectra were recorded for 8 sec/point at 1 nm intervals between 260 and 184 nm using
0.01 cm cuvettes. No signal processing (smoothing) was used.
Figure 5. Disulfide formation in a reduced model peptide in the presence of
Sptrx1 or PDI . A) Using 2 mM GSH and 0.5 mM GSSG and B) using 1 m M selenite as
electron acceptor. The reaction was performed in 100 µl buffer consisting of 100 mM Tris-
Cl pH 7.4, 200 mM KCl and 1 mM EDTA. The reaction was initiated by addition of
peptide to a final concentration of 20 µM. Aliquots were removed and quenched at
different time points by addition of HCl to a final concentration of 0.2 M. The samples
were analyzed immediately on reverse phase HPLC (Pharmacia SMART system) on a
C18 column (2.1 mm x 10 cm) using a linear gradient 0f 5-25% acetonitrile, 0.1% TFA for
25 min at a flow rate of 100 µl/min. The fraction of oxidized peptide was calculated from
the total peak area in the chromatogram. Open squares, PDI; Black triangles, Sptrx-1;
Open circles, background.
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